VCYT VERACYTE, INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1384101 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY318.4%
TTM EPS YoY305.3%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—
Margins
Gross margin72.0%
Operating margin17.1%
Net margin21.8%
FCF margin27.8%
EBITDA margin20.8%
Returns
ROE9.4%
ROA8.6%
ROIC (approx.)9.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets8.9%
Debt / equity0.00x
Current ratio5.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $151.75M | $150.32M | $139.07M | $140.64M | $131.87M | $130.16M | $114.47M | $118.63M |
| Gross profit | $107.10M | $108.55M | $101.16M | $101.97M | $91.28M | $89.77M | $79.51M | $78.75M |
| R&D expense | $32.16M | $29.44M | $27.10M | $20.85M | $15.98M | $16.26M | $17.72M | $19.29M |
| SG&A expense | $29.30M | $27.44M | $23.68M | $17.37M | $27.28M | $32.33M | $33.81M | $26.91M |
| Operating income | $16.57M | $22.98M | $22.65M | $37.20M | $22.95M | -$5.27M | $2.90M | $4.17M |
| Pretax income | $21.12M | $26.52M | $29.97M | $40.63M | $18.89M | $1.25M | $7.43M | $3.44M |
| Income tax | -$10.38M | $1.03M | $1.27M | -$515,000 | -$248,000 | $2.23M | $381,000 | -$1.67M |
| Net income | $31.50M | $25.49M | $28.71M | $41.15M | $19.14M | -$980,000 | $7.05M | $5.11M |
| EBITDA | $22.55M | $27.82M | $28.08M | $42.49M | $28.21M | $221,000 | $8.27M | $10.43M |
| EPS (basic) | 0.39 | 0.32 | 0.36 | — | 0.24 | -0.01 | 0.09 | — |
| EPS (diluted) | 0.38 | 0.31 | 0.35 | — | 0.24 | -0.01 | 0.09 | — |
| Weighted avg. shares (diluted) | 82.78M | 82.06M | 81.31M | — | 79.69M | 78.39M | 80.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $199.83M | $299.52M | $263.14M | $362.58M | $317.21M | $221.15M | $187.76M | $240.63M |
| Short-term investments | — | — | — | $50.31M | — | — | — | — |
| Receivables | $56.79M | $54.18M | $50.11M | $44.66M | $47.83M | $50.81M | $53.78M | $46.52M |
| Inventory | — | — | — | $20.55M | $20.33M | $25.02M | $24.25M | $21.75M |
| Current assets | $467.88M | $574.77M | $522.17M | $488.38M | $449.22M | $414.68M | $383.15M | $372.27M |
| PP&E, net | $24.87M | $21.93M | $22.65M | $22.19M | $18.90M | $18.55M | $22.53M | $22.95M |
| Goodwill | $855.58M | $767.15M | $767.15M | $767.15M | $767.15M | $773.25M | $754.27M | $745.80M |
| Intangibles | $184.88M | $82.70M | $85.86M | $89.15M | $92.48M | $95.81M | $99.09M | $102.30M |
| Total assets | $1.57B | $1.49B | $1.44B | $1.41B | $1.37B | $1.34B | $1.32B | $1.30B |
| Current liabilities | $84.21M | $62.74M | $56.12M | $59.94M | $72.15M | $76.43M | $75.12M | $78.63M |
| Total liabilities | $139.99M | $97.96M | $91.99M | $96.44M | $110.12M | $123.05M | $120.47M | $124.07M |
| Shareholders' equity | $1.43B | $1.39B | $1.34B | $1.31B | $1.26B | $1.22B | $1.19B | $1.18B |
| Shares outstanding | 80.66M | 80.36M | 79.79M | 79.36M | 79.03M | 78.60M | 78.31M | 77.77M |
| Cash flow statement | ||||||||
| Operating cash flow | $40.26M | $45.83M | $35.22M | $52.58M | $44.76M | $33.60M | $5.36M | $24.52M |
| Capital expenditure | $2.33M | $2.86M | $2.96M | $3.78M | $2.79M | $1.29M | $1.82M | $4.14M |
| Free cash flow | $37.92M | $42.97M | $32.25M | $48.80M | $41.97M | $32.32M | $3.54M | $20.38M |
| Investing cash flow | -$139.47M | -$13.54M | -$127.96M | -$5.43M | $48.26M | -$224,000 | -$51.82M | -$54.14M |
| Financing cash flow | -$479,000 | $4.14M | -$6.63M | -$149,000 | $2.98M | -$566,000 | -$6.48M | -$4.51M |
| Depreciation & amortization | $5.98M | $4.84M | $5.43M | $5.30M | $5.27M | $5.49M | $5.36M | $6.25M |
| Stock-based compensation | $13.96M | $14.09M | $12.76M | $10.90M | $10.76M | $10.98M | $10.96M | $9.63M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.